Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune ...

Across both mice and humans, we found that males tended to recover from pain more quickly than females. The reason appears to ...

In Switzerland, 0.02% of the population lives beyond the age of 100. Could there be biological characteristics associated ...

Phase III study will be "sufficient and pivotal for registration in the U.S." Kiniksa Pharmaceuticals ( KNSA 8.12%) ...

Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net ...

NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") ...

In 2024, the FDA granted 510(k) clearance to a hemodialysis machine capable of delivering online high-volume hemodiafiltration. Since then, companies have started phased introduction of the system ...

Researchers with the Knight Initiative for Brain Resilience have modified a well-known immune protein to spark the growth of new neurons, ease brain inflammation, and improve cognition in old mice.

Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

The start of 2026 has been a period of strong execution and momentum across our clinical programs, broadly, and with ATI-052 specifically,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “The ...

Women are more likely to experience chronic pain, studies have found, and their pain lasts longer, on average. New research ...